-
Innovation Ranking
NewInnovation Ranking – Polaris Inc
Polaris Inc (Polaris), formerly Polaris Industries Inc is a manufacturer of automobiles. The company specializes in designing, engineering and producing off-road vehicles (ORV), which include all-terrain vehicles (ATV) and side-by-side vehicles for recreational and utility use, motorcycles, small vehicles (SV) and snowmobiles. The product portfolio of the company includes side by side vehicles, all-terrain vehicles, snowmobiles, commercial utility vehicles and personal quadricycles. The company also provides related replacement parts, garments and accessories (PG&A). Its services include financing, insurance services and...
-
Thematic Analysis
NewGlobal Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-319 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-319 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-319 in Follicular Lymphoma Drug Details: ABBV-319 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Metastatic Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Metastatic Prostate Cancer Drug Details: ALG.APV-527 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Mantle Cell Lymphoma Drug Details: Fenebrutinib (GDC-0853, RG-7845)...
-
Sector Analysis
United States (US) Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
US Defense Market Report Overview The US defense budget was worth $818.8 billion in 2023, which was a 10.7% rise from the previous year. This is in response to the deteriorating global security environment such as the Russian invasion of Ukraine and continued tensions with China over territory in the South China Sea and wider Indo-Pacific. Numerous geo-strategic and domestic political imperatives continue to drive US expenditure as defense capabilities gain growing political importance. The country’s defense budget is expected to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Malignant Pleural Mesothelioma Drug Details: Pegargiminase (ADI-PEG 20) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Pegargiminase (ADI-PEG...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Leiomyosarcoma Drug Details: Pegargiminase (ADI-PEG 20) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Non-Small Cell Lung Cancer Drug Details: MHB-088C...